437 related articles for article (PubMed ID: 24922589)
1. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Babu A; Wang Q; Muralidharan R; Shanker M; Munshi A; Ramesh R
Mol Pharm; 2014 Aug; 11(8):2720-33. PubMed ID: 24922589
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer.
Schumann C; Chan S; Khalimonchuk O; Khal S; Moskal V; Shah V; Alani AW; Taratula O; Taratula O
Mol Pharm; 2016 Jun; 13(6):2070-83. PubMed ID: 27170529
[TBL] [Abstract][Full Text] [Related]
3. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice.
Kim JH; Kim YS; Park K; Lee S; Nam HY; Min KH; Jo HG; Park JH; Choi K; Jeong SY; Park RW; Kim IS; Kim K; Kwon IC
J Control Release; 2008 Apr; 127(1):41-9. PubMed ID: 18234388
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
6. Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: role of autophagy.
Zhang N; Dai L; Qi Y; Di W; Xia P
Int J Oncol; 2013 Jun; 42(6):2053-9. PubMed ID: 23592281
[TBL] [Abstract][Full Text] [Related]
7. [Inhibition of mitochondrial Smac release by Akt in chemoresistant ovarian cancer cells].
Yang XK; Wang JD; Wang SY; Zhang YX
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):259-62. PubMed ID: 18788627
[TBL] [Abstract][Full Text] [Related]
8. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
9. Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling.
Koch M; Krieger ML; Stölting D; Brenner N; Beier M; Jaehde U; Wiese M; Royer HD; Bendas G
Biochem Pharmacol; 2013 Apr; 85(8):1077-90. PubMed ID: 23396090
[TBL] [Abstract][Full Text] [Related]
10. Dual drug-loaded biofunctionalized amphiphilic chitosan nanoparticles: Enhanced synergy between cisplatin and demethoxycurcumin against multidrug-resistant stem-like lung cancer cells.
Huang WT; Larsson M; Lee YC; Liu DM; Chiou GY
Eur J Pharm Biopharm; 2016 Dec; 109():165-173. PubMed ID: 27793756
[TBL] [Abstract][Full Text] [Related]
11. Targeted silencing of Survivin in cancer cells by siRNA loaded chitosan magnetic nanoparticles.
Unsoy G; Gunduz U
Expert Rev Anticancer Ther; 2016 Jul; 16(7):789-97. PubMed ID: 27130312
[TBL] [Abstract][Full Text] [Related]
12. Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin.
Khan MM; Madni A; Torchilin V; Filipczak N; Pan J; Tahir N; Shah H
Drug Deliv; 2019 Dec; 26(1):765-772. PubMed ID: 31357896
[TBL] [Abstract][Full Text] [Related]
13. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
14. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
Yan XD; Li M; Yuan Y; Mao N; Pan LY
Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
[TBL] [Abstract][Full Text] [Related]
15. Encapsulation of verapamil and doxorubicin by MPEG-PLA to reverse drug resistance in ovarian cancer.
Zheng W; Li M; Lin Y; Zhan X
Biomed Pharmacother; 2018 Dec; 108():565-573. PubMed ID: 30243090
[TBL] [Abstract][Full Text] [Related]
16. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
17. Enhanced anti-topoisomerase II activity by mucoadhesive 4-CBS-chitosan/poly (lactic acid) nanoparticles.
Songsurang K; Suvannasara P; Phurat C; Puthong S; Siraleartmukul K; Muangsin N
Carbohydr Polym; 2013 Nov; 98(2):1335-42. PubMed ID: 24053811
[TBL] [Abstract][Full Text] [Related]
18. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.
Fraser M; Leung BM; Yan X; Dan HC; Cheng JQ; Tsang BK
Cancer Res; 2003 Nov; 63(21):7081-8. PubMed ID: 14612499
[TBL] [Abstract][Full Text] [Related]
19. Chitosan/PLA nanoparticles as a novel carrier for the delivery of anthraquinone: synthesis, characterization and in vitro cytotoxicity evaluation.
Jeevitha D; Amarnath K
Colloids Surf B Biointerfaces; 2013 Jan; 101():126-34. PubMed ID: 22796782
[TBL] [Abstract][Full Text] [Related]
20. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
